Maxcyte (MXCT) Cost of Revenue (2020 - 2026)

Maxcyte (MXCT) has 7 years of Cost of Revenue data on file, last reported at $1.6 million in Q1 2026.

• Quarterly Cost of Revenue rose 4.81% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$247000.0 (up 96.98% YoY) and the FY2025 annual result came in at $6.2 million, down 12.37% from the prior year.
• Cost of Revenue improved to $1.6 million in Q1 2026 per MXCT's latest filing, from -$9.2 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $7.2 million in Q4 2023 and bottomed at -$13.1 million in Q4 2024.
• The 5-year median for Cost of Revenue is $1.5 million (2024), against an average of $406982.4.
• The widest annual swing landed in 2023, when Cost of Revenue jumped 474.44%; it then slumped 281.85% in 2024.
• Tracing MXCT's Cost of Revenue over 5 years: stood at -$8.2 million in 2022, then jumped by 188.0% to $7.2 million in 2023, then tumbled by 281.85% to -$13.1 million in 2024, then rose by 29.72% to -$9.2 million in 2025, then surged by 117.06% to $1.6 million in 2026.
• Per Business Quant, the three latest MXCT Cost of Revenue figures stand at $1.6 million (Q1 2026), -$9.2 million (Q4 2025), and $1.6 million (Q3 2025).

Peer Comparison